Transcend Therapeutics is a clinical-stage, neuroscience-focused company developing next-generation psychoactive medicines for neuropsychiatric disease. Transcend develops medicines that are accessible to a larger percentage of patients in need, specifically the tens of millions of patients who already take psychotropic medication. We have real-world data showing that our lead product provided significant benefit to >85% of patients with PTSD and depression. We have already advanced our lead compound into an approved Phase II study in PTSD, with plans to expand into depression and other indications.
Transcend's leadership team includes the first scientist to receive federal funding for clinical psychedelic research in over 50 years and drug development executives with pivotal contributions to 13 FDA approvals, including the most recently approved drug for depression, and $7B dollars in M&A and public company value. We are backed by AlleyCorp, an incubator and venture capital fund that has founded some of the most transformative companies in New York, including MongoDB, Business Insider, Gilt Groupe, Zola, Nomad Health, and many others. AlleyCorp incubations have collectively raised $1B+ in venture capital with an aggregate value of $30B+.
As a Public Benefit Corporation, we have pledged 10% of founding shares toward nonprofits focused on scientific research and patient access.
Transcend's leadership team includes the first scientist to receive federal funding for clinical psychedelic research in over 50 years and drug development executives with pivotal contributions to 13 FDA approvals, including the most recently approved drug for depression, and $7B dollars in M&A and public company value. We are backed by AlleyCorp, an incubator and venture capital fund that has founded some of the most transformative companies in New York, including MongoDB, Business Insider, Gilt Groupe, Zola, Nomad Health, and many others. AlleyCorp incubations have collectively raised $1B+ in venture capital with an aggregate value of $30B+.
As a Public Benefit Corporation, we have pledged 10% of founding shares toward nonprofits focused on scientific research and patient access.
Location: United States, New York
Employees: 1-10
Total raised: $40M
Founded date: 2021
Founders name: Blake Mandell
Investors 2
| Date | Name | Website |
| - | Brown Ange... | brownangel... |
| - | Alpha Wave... | alphawaveg... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 24.02.2023 | Series A | $40M | Emerald De... |
Persons 2
| Date | First Name | Last Name | Title | Location | |||
| - | Blake | Mandell | Co-Founder... | linkedin.c... | - | b***e@tran... | - |
| - | Stephanie | Galinos | Senior Cli... | linkedin.c... | - | s*******e@... | - |
Mentions in press and media 4
| Date | Title | Description |
| 10.10.2024 | Innovative mental health research partnership launches to study new therapies | People across Cambridgeshire and Peterborough with severe mental health conditions now have the opportunity to take part in local groundbreaking clinical trials, to assess if empathogens and psychedelics can help people with treatment-resis... |
| 24.02.2023 | Transcend Therapeutics Announces $40 million Series A Funding | Transcend Therapeutics, a biotechnology company that develops medicines to treat neuropsychiatric diseases, including post-traumatic stress disorder (PTSD), today announced that it closed its Series A funding round of $40 million. Led by Al... |
| 23.02.2023 | Transcend Therapeutics Raises $40M in Series A Funding | Transcend Therapeutics, a New York-based mental health-focused biotechnology company, raised $40M in Series A funding. The round was led by Alpha Wave Global and Integrated Investment Partners with participation from Global Founders Capital... |
| - | Transcend Therapeutics | “Transcend Therapeutics is a biotechnology company discovering, developing and delivering the next generation of psychoactive compounds focused on patient access to create a world where people no longer suffer with neuropsychiatric disease.... |